Glenmede Trust’s Concentrix CNXC Stock Holding History

Glenmede Trust’s Portfolio CNXC Stock Details CNXC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-12,139	Closed	-$1.62M	–	1297
2022 Q4	$1.62M	Buy	12,139 +86	+0.7%	+$10.5K	0.01%	562
2022 Q3	$1.34M	Buy	+12,053	New	+$1.54M	0.01%	583

Other funds holding CNXC

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Impactive Capital New York City, New York $1.4B AUM 13.97% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Lyrical Asset Management New York $7.88B AUM 36.5% 1-Year Est. Return

Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return

Glenmede Trust's CNXC Position: Q1 2023 in Review

Glenmede Trust sold out of Concentrix (CNXC) in Q1 2023, closing a stake of 12,139 shares — an estimated $1.62M sold.

Glenmede Trust first reported a position in CNXC in Q3 2022 and held it in 2 quarters. The position peaked at $1.62M in Q4 2022. 324 funds tracked by Wall St. Rank hold CNXC as of Q1 2023.

Glenmede Trust reported no remaining Concentrix position as of Q1 2023 after selling out during the quarter.
Glenmede Trust sold 12,139 Concentrix shares in Q1 2023, an estimated $1.62M.
Glenmede Trust first reported a position in Concentrix in Q3 2022 and held it in 2 quarters.
Glenmede Trust's Concentrix position peaked at $1.62M in Q4 2022.
324 funds tracked by Wall St. Rank held Concentrix as of Q1 2023.

Based on Glenmede Trust's 13F filing for Q1 2023, filed 15 May 2023.